Drug Profile
ACH 126447
Alternative Names: ACH-126447; HelioxanthinLatest Information Update: 05 Feb 2020
Price :
$50
*
At a glance
- Originator Achillion Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis B; Hepatitis C
Most Recent Events
- 28 Jan 2020 Achillion Pharmaceuticals has been acquired by Alexion Pharmaceuticals
- 21 Mar 2007 Discontinued - Preclinical for Hepatitis B in USA (unspecified route)
- 21 Mar 2007 Discontinued - Preclinical for Hepatitis C in USA (unspecified route)